Retrospective Analysis of Early Stage Mucinous Ovarian Cancersystematic Lymphadenectomy May Be Omitted

Author(s): Ning Li, Guangwen Yuan, Xiaoguang Li, Hongwen Yao, Yan Song, Lingying Wu

Purpose: Mucinous ovarian cancer is a less common epithelial ovarian cancer. Mucinous early stage ovarian cancer (mEOC) seems less aggressive than other histologic types and require more conservative treatment. This analysis was conducted to explore the clinical outcome and appropriate treatment of mEOC.

Methods: Data was extracted from patients with stage I/II ovarian cancer from 1999 to 2010 at our institution. Patients were classified into mucinous group (n=45) and non-mucinous groups (n=159). Clinical features and survival outcomes were compared between the two groups.

Results: The 3-year/5-year progression free survival (PFS) of the mucinous were significantly longer than the non-mucinous group (96% /91.0% vs. 82.4% /75.1%, P=0.01). 40.0% of mEOC patients underwent systematic lymphadenectomy, and there was no significant differences of recurrence rate whether they received this procedure. 35.6% patients of mEOC underwent FSS and none of them experienced recurrence. 68.8% of mEOC patients received adjuvant chemotherapy.

Conclusion: mEOC has longer PFS than other histologic types. Systematic lymphadenectomy may be omitted in mEOC patients.

© 2016-2024, Copyrights Fortune Journals. All Rights Reserved